119th Congress · introduced in the House · Apr 16, 2026
Drug Origin Transparency Act of 2026
Official title from Congress.gov
Latest action (Apr 16, 2026): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
6 citations.
VIZIENT INC · lobbying firm or registrant: VIZIENT, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$300,000
Spent on own lobbying
…tion and increased notification by manufacturers for surges in demand. Continued monitoring and encouraged passage of the Drug Origin Transparency Act of 2026 (HR.8339). Hospital Data and Analytics - Provided education on the types of clinical, operational, financial and quality data hospitals collect and monitor to improve p…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$80,000
Spent on own lobbying
…of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. H.R. 8339: Drug Origin Transparency Act to amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting H.R. 5526/S. 1954: B…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR ACCESSIBLE MEDICINES · lobbying firm or registrant: ASSOCIATION FOR ACCESSIBLE MEDICINES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Pharmacy
$870,000
Spent on own lobbying
…(CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. H.R.7148: Consolidated Appropriations Act, 2026 as it relates to PBM reforms and Q1/Q2. H.R.8339: Drug Origin Transparency Act of 2026.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIZIENT INC · lobbying firm or registrant: VIZIENT, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$320,000
Spent on own lobbying
…der communication and increased notification by manufacturers for surges in demand Endorsed and encouraged passage of the Drug Origin Transparency Act of 2026 (HR.8339) Hospital Data and Analytics - Provided education and information on the types of clinical, operational, financial and quality data hospitals collect and monit…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$480,000
Spent on own lobbying
…of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. H.R. 8339: Drug Origin Transparency Act to amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting H.R. 5526/S. 1954: B…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIZIENT INC · lobbying firm or registrant: VIZIENT, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$320,000
Spent on own lobbying
…re providers, as well as key differences between traditional GPOs and PBMs. Monitored development and introduction of the Drug Origin Transparency Act of 2025 (HR.8339) Monitored development and passage of the Consolidated Appropriations Act, 2026 (H.R. 7148) Payer-mandated White Bagging - Urged support for policy updates rel…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing